Salute e Benessere

Tessa Therapeutics' 'Off-the-Shelf' CAR-T Therapy Shows Promising Results in…

78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data encouraging with no graft-versus-host-disease and no neurotoxicityUpdated data highlighted in podium presentation at the 17 thInternational Conference on Malignant Lymphoma expand upon favorable results presented at 2022 Annual Meeting of American Society of Hematology (ASH) SINGAPORE, June15, 2023(GLOBE NEWSWIRE) --Tessa...

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine…

Novavax presented data at the VRBPAC meeting that supports the recommendation to vaccinate this fall with a monovalent XBB strain. Novavax data showed that its XBB.1.5 COVID vaccine candidate induced functional immune responses for XBB.1.5, XBB.1.16 and XBB.2.3 variants, indicating a broad response that could potentially be applicable for forward-drift variants. Novavax presented data at the VRBPAC meeting that supports the recommendation to vaccinate this fall with a monovalent XBB strain...

Next-generation Sequencing Services Market size to grow by USD 30.14 billion…

Next-generation Sequencing Services Market: Overview Next-generation Sequencing Services Market: Overview Next-generation sequencing technology is utilized to improve the non-conventional and conventional applications to extract deep insights at the genome levels. NGS is able to leverage the existing applications because of the improvements in analytical solutions, services, ancillary protocols, and automation in this aspect. These upgrades offer scope for implementing next-generation...

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating…

Mechelen, Belgium;15June 2023,22:01 CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023 . Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ: GILD) . He brings 30 years of global finance and operational...

The Plastic Labware Market to be Worth $19 Billion by 2026, Growing Demand for…

Browse In-Depth TOC of the Plastic Labware Market Browse In-Depth TOC of the Plastic Labware Market 117 - Tables 78 - Charts 302 – Pages In recent years, there has been a growing demand for eco-friendly plastic labware products, and many manufacturers have shifted toward using biodegradable and compostable plastics to reduce their environmental impact. This trend is expected to drive the growth of the plastic labware market in the upcoming years...

Metal Forging Market to Reach $168 Billion, Globally, by 2032 at 7.2% CAGR…

Download Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/75325 Download Free Sample Report @https://www.alliedmarketresearch.com/request-sample/75325 Prime Determinants of Growth: The market for global metal forging is experiencing growth due to several factors, such as industrial expansion in the automotive and aerospace sectors, growth in the energy industry, and industrialization. However, the limitations associated with the metal forging process...

Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program…

Leuven, BELGIUM, Boston, MA, US –June 15 , 2023 – 7 pm CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 3 of funding under the Subscription Agreement with Atlas Special Opportunities LLC (" Atlas ”). On June 15, 2023, the Company issued 40 convertible bonds to Atlas totaling EUR one million...

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 6convertible bonds in Oxurion resulting in a EUR 150 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US–...

Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO to Advance…

Danvatirsen is an antisense oligonucleotide (ASO) that selectively targets STAT3 and has shown clinical activity in two Phase II clinical studies. Danvatirsen binds to STAT3 mRNA, inducing breakdown of the transcript. Currently, danvatirsen is planned to continue Phase 2 clinical development for head and neck squamous cell carcinoma to advance the program through key clinical milestones and data readouts. Flamingo is also advancing FTX-001, Flamingo's most advanced long non-coding RNA (LncRNA)…

Vivoryon Therapeutics N.V. Announces CEO Transition Plan

Vivoryon Therapeutics N.V.Announces CEO Transition Plan Dr. Ulrich Dauer not to extend current term running through 2024 AGMBoard to initiate succession planning Halle (Saale) / Munich, Germany , June 15 , 2023– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered...

Digital Pathology Market worth $1.8 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844 Browse in-depth TOC on "Digital Pathology Market" 248 - Tables 48 - Figures 274 - Pages Digital Pathology Market Scope: The human pathology segment has accounted for the largest market share during the forecast period. Based on type, the digital pathology market is...

Global Gastric Cancer Market Predicted to Make a Strong Comeback after the…

As per the report published by Research Dive, the global gastric cancer market is envisioned to garner a revenue of $10,737.00 million and grow at a fascinating CAGR of 17.9% over the estimated timeframe from 2022 to 2031. As per the report published by Research Dive, theglobal gastric cancer marketis envisioned to garner a revenue of$10,737.00 millionand grow at a fascinating CAGR of 17.9% over the estimated timeframe from 2022 to 2031. Segments of the Gastric Cancer Market ...

Press release Biocartis Group NV: Biocartis announces planned operational…

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 15 June 2023, 17:15 CESTBIOCARTIS ANNOUNCES PLANNED OPERATIONAL REORGANIZATION AND COST REDUCTION PROGRAM Focusing investments on near-term product revenue generation and strategic partnerships that are expected to drive sustainable growthApproximately EUR 18 million of annualized cost reductions Cost reductions across the organization to create a clear path to break-even EBITDA 1by...

Metastatic Pancreatic Cancer Market to Proliferate Immensly, Predicts…

Key Takeaways from the Metastatic Pancreatic Cancer Market Report Key Takeaways from the Metastatic Pancreatic Cancer Market Report Discover which therapies are expected to grab the major metastatic pancreatic cancer market share @Metastatic Pancreatic Cancer Market Report Metastatic Pancreatic Cancer Overview Pancreatic cancer is one of the most dangerous malignant tumor forms, accounting for the 4th and 5th major causes of cancer death inthe United Statesand the...

The Non-viral Transfection Reagents and Systems Market is anticipated to grow at…

With increasing focus on genetically modified therapies, there is a consequent rise in the demand for efficient gene delivery vectors and innovators are actively evaluating the potential of non-viral transfection agents. Driven by the growing demand for cell and gene therapies, and the ongoing efforts of industry stakeholders, the non-viral transfection reagents and systems market is anticipated to grow at a steady pace in the foreseen future. With increasing focus on genetically modified...

Spinal Cord Stimulation Devices Market to Reach $4.8 Billion, Globally, by 2032…

Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/3792 Download Sample Copy-https://www.alliedmarketresearch.com/request-sample/3792 Prime Determinants of Growth: The spinal cord stimulation devices market is experiencing growth due to several factors, such as an increase in the prevalence of chronic pain conditions, technological advancements in spinal cord stimulation devices, and the availability of medical reimbursement schemes. However, the high...

Steam Turbine Market to Reach $22.4 Billion, Globally, by 2032 at 2.6% CAGR…

Request PDF Brochure: https://www.alliedmarketresearch.com/request-sample/6028 Request PDF Brochure: https://www.alliedmarketresearch.com/request-sample/6028 Drivers, Restraints, and Opportunities- The global steam turbine market is experiencing rapid growth worldwide, owing to factors such as a rise in demand for energy and a reduction in the production of energy from fossil sources. On the other hand, the higher efficiency of other turbines restricts market growth. However,...

Anti-Ageing Drugs Market to Amass Notable Gains by 2029 Says Brandessence Market…

Key Takeaways Key Takeaways Anti-Ageing Drugs Market is anticipated to generate significant returns over the stipulated timeline of 2022-2029. Get Sample of Report@ https://brandessenceresearch.com/downloadSample/PostId/450 Elaborating the Key Trends and Dynamics of Anti-Ageing Drugs Market Rise in the geriatric population base coupled with the growing prevalence of age-related chronic and lifestyle-based disorders are the primary factors augmenting the outlook of this...

NABR Files Petition Challenging the Listing of Long-Tailed Macaque by the IUCN

"The listing of the long-tailed macaque as endangered by the IUCN sets a dangerous precedent because this determination is not based on peer-reviewed scientific information. This is particularly troubling because arbitrary actions like this make life-saving medical research even more difficult to conduct in the U.S. and other countries." "The listing of the long-tailed macaque as endangered by the IUCN sets a dangerous precedent because this determination is not based on…

New patent for Infant Bacterial Therapeutics has been approved in Europe

Infant Bacterial Therapeutics AB (IBT) announces today that the European Patent Office has approved its patent application for Lactobacillus reuteri. The patent pertains to the drug candidate IBP-9414, currently undergoing Phase III development by IBT for the prevention of Necrotizing Entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants. The invention encompasses a unique method of activating freeze-dried bacteria. The patent reinforces the existing protection for...

IBA and PARTICLE initiate FLASH proton therapy Research Partnership

First FLASH research project to be conducted in a Proteus ® ONE treatment room with a superconducting synchrocyclotronLouvain-La-Neuve, Belgium, June 15, 2023 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, and PARTICLE (Particle Therapy Interuniversity Center Leuven), located on the health sciences campus of the University Hospitals Leuven (UZ...

SHEIN Teams up With Global Sellers and Brands to Launch Full Category Sales

SHEIN has also reached agreements with esteemed global brands to sell their products on its marketplace. Brands like Skechers, a leading footwear company known for its innovative designs, Lansinoh, a trusted name in mother-care products, have all onboarded to SHEIN's marketplace. Moreover, SHEIN is collaborating with prominent global multi-label boutiques to bring an extensive collection of fashion, beauty and lifestyle brands to its marketplace. SHEIN has also reached agreements with…

BGI Genomics Unveils Genalive's Cutting-Edge Clinical Lab in Saudi Arabia

Genalive combines BGI Genomics' cutting-edge genomic technologies and Tibbiyah's clinical expertise to offer comprehensive genetic testing and precision medicine solutions. Equipped with state-of-the-art facilities and staffed by a team of highly skilled professionals, Genalive is dedicated to translating genomic insights into personalized therapies. This laboratory is equipped with high-throughput sequencing platforms, advanced bioinformatics pipelines, and AI-driven analytical tools to drive…

REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S…

HER2DX® genomic test was applied in 292 (82.0%) baseline pre-treatment tumor biopsies. The HER2DX® pCR-score was found to be significantly associated with pCR, regardless of the treatment regime, 18F-FDG-PET metabolic response, and hormone receptor status. Despite a short median follow-up of 3.6 years, 85.0% and 100.0% of events were identified as high-risk according to the 2 pre-specified cutoffs of the HER2DX® risk-score. In contrast, 98% and 100% of patients with HER2DX® low-risk were…

Altri Comunicati